INNIO N.V. Ordinary Shares vs Inovio Pharmaceuticals Inc — how do they compare? INNIO N.V. Ordinary Shares trades at $16 (market cap $13.73B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $103.19M). The key difference: INNIO N.V. Ordinary Shares is far larger — about 133.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| INIO | INO | |
|---|---|---|
Market Cap | $13.73B | $103.19M |
Volume | 5,012,195 | 8,461,580 |
Sector | Industrials | Health |
52-Week High | $41.13 | $2.60 |
52-Week Low | $16.50 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $15.39B | $74.52M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.
Read more on INIO →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →